Genekor Medical S.A.

Advances in #genetics offer opportunities for early diagnosis and prevention of hereditary diseases, leading to more effective treatments. #GeneticCounseling ensures that this valuable information benefits the entire family. At #Genekor, we provide genetic counseling free of charge to all our patients. Learn More: https://lnkd.in/dy7iySfM

🇷🇴 This month, Genekor Romania had the opportunity to take part in two significant conferences.   📍 From October 10-12, 2024, we attended the National Oncology Congress (S.N.O.M.R) in Poiana Brașov, where we had the opportunity to connect with key professionals in the field at our booth. 📍 Earlier in the month, from October 3-5, 2024, we also participated in the XIVth Medical Genetics Conference at the University of Medicine, Pharmacy, Science, and Technology “George Emil Palade” in Târgu Mureș. We were able to engage with professionals at our booth, discussing innovations in genetic testing and diagnostics.   #Genekor #Oncology #MedicalGenetics #SNOMR

🎗️Today, on World Breast Cancer Awareness Day, Eftychia Deligiorgi shares her story about her decision to undergo the HerediGENE® genetic test for hereditary cancer, reminding us of the importance of prevention. The positive result for the 𝘉𝘙𝘊𝘈2 gene led her to take decisive preventive steps by proceeding to a prophylactic mastectomy and later a prophylactic oophorectomy. Having a 𝘉𝘙𝘊𝘈 mutation means you have a likelihood of 45% to 85% for developing #breastcancer in your lifetime, along with a 10% to 46% chance of ovarian cancer. Prevention saves lives! We owe it to ourselves and to those who did not have this option, as Eftychia emphasizes. Read her full story on The Toc: https://lnkd.in/gWFq4AYA Genekor News: https://lnkd.in/gq-Z8_YN

We’re pleased to share that our Pathology Lab in Thessaloniki now offers the FRα test, essential for prescribing mirvetuximab soravtansine to patients with platinum-resistant #ovariancancer. The test supports the use of mirvetuximab soravtansine for FRa-positive patients who have received 1-3 lines of treatment, following the EMA’s positive opinion in September 2024 and FDA approval in March 2024. 🔬 Our lab uses the Ventana BenchMark Ultra platform, ensuring precise and reliable results. Find out more about the Frα test: https://lnkd.in/d9aQZRzH #Genekor

➡️ The clinical utility of genetic testing in hereditary pancreatic cancer During Genekor's participation in the conference "From Oncogenesis to Therapy," Varvara Kevisa Potska, MSc, member of Genekor's hereditary Cancer team, presented the study conducted in our laboratory on the multi-gene screening of 184 patients with pancreatic cancer using next-generation sequencing (#NGS) technology. 📍 The results of the study showed that a pathogenic/likely pathogenic variant was identified in 21% of pancreatic cancer patients. These findings may benefit physicians in the clinical management of their patients and the selection of an appropriate therapeutic approach, as well as the individuals themselves and their family members regarding their family planning and the investigation of the transmission of pathogenic genes to immediate relatives. #Genekor #pancreaticcancer #hereditarycancer

We are excited to have once again participated in the International Breastanbul Congress 2024 in Istanbul, Turkey! 🇹🇷🎗️ A special thank you to Prof. Başak Oyan Uluç, MD and Prof. Christos J. Markopoulos, MD who gave an outstanding Satellite Symposium on the subject of: “Why and When to Ask or Not for Oncotype DX®”. Using numerous case studies and data from the TAILORx and RxPONDER trials they thoroughly discussed the significance of Oncotype DX® testing in HR+, HER2-early breast cancer patients at clinical practice and how the results shape chemotherapy decisions. It was strongly emphasized how crucial Oncotype DX® test is, how it prevents over and undertreatment, and that clinical-pathological features cannot predict the outcome of Recurrence Score®. For these reasons, the International Guidelines continue to recommend the Oncotype DΧ© test, which has the highest level of evidence. #Genekor #BREASTANBUL2024 #BreastCancer #OncotypeDX

We're #hiring a new Customer Service Representative in Attiki. Apply today or share this post with your network.

🌍 Genekor is attending BREASTANBUL 2024 in Istanbul, Turkey. Join us at📍Booth #23 from October 10-12, 2024, at the Wyndham Grand İstanbul Levent Hotel, Turkey. Don't miss our Satellite Symposium on October 11 at 10:30 a.m., Hall C, where Prof. MD Markopoulos and Prof. MD Başak Oyan Uluç will present: "𝗪𝗵𝘆 𝗮𝗻𝗱 𝗪𝗵𝗲𝗻 𝘁𝗼 𝗔𝘀𝗸 𝗼𝗿 𝗡𝗼𝘁 𝗳𝗼𝗿 𝗢𝗻𝗰𝗼𝘁𝘆𝗽𝗲 𝗗𝗫." This is a great opportunity to learn more about the critical role of OncotypeDX in early-stage breast cancer treatment decision-making. #Genekor #meetus #BreastCancer #BREASTANBUL2024

🔬 We are excited to announce the opening of another Genekor Pathology Laboratory, now in Bucharest! 🇷🇴 With our state-of-the-art facilities and experienced scientific staff, Genekor is committed to delivering the highest quality pathology services to support physicians and healthcare providers. Our new lab in Bucharest is designed to offer precise and reliable results, for the accurate diagnosis, prognosis and treatment of patients. 👉Learn more about the Pathology Lab services in Romania reimbursed by the National Health Insurance House of Romania: https://lnkd.in/dBfkEhtz 📍 Lab Address: Nicolae Caramfil, Nr. 53, Cod Postal: 014145, Sector 1, București, Romania 📞 Contact: +40 31 228 9800 #Genekor #PathologyLab #Bucharest

Genekor participated with two important presentations at the Scientific Conference "Breast Diseases in Obstetrics and Gynecology: From Diagnosis to Treatment," which took place at the Mediterranean Palace in Thessaloniki on Saturday, October 5th. ➡️ George Kapetsis, Medical Manager - "The Contribution of the Oncotype DX® Test in the Management of Breast Cancer" His presentation highlighted the clinical utility of the #OncotypeDX® genomic signature for #HR+, #HER2- #early-stage #breastcancer. The test allows patients and physicians to determine the risk of cancer recurrence and predicts whether the patient will benefit from chemotherapy, thus helping doctors to design personalized treatments and avoid unnecessary therapies. By presenting clinical study data, he emphasized that Oncotype DX® stands out as the most valuable molecular signature, as reflected in the relevant international guidelines showcased. ➡️ Spyros Giannoulakis, Scientific Training and Development Manager - "BRCA1,2 or Multigene Panel?" In his talk, he discussed the clinical utility of the multigene panel in gynaecological cancers (#breastcancer, #ovariancancer, and #endometrialcancer). He also referred to other important genes beyond BRCA1/2 that play a crucial role in the management of patients, according to international guidelines, utilizing clinical data and case studies from #Genekor's laboratory.